Long-term effects of almitrine bismesylate in COPD patients with chronic hypoxaemia

Respiratory Medicine

Volumn 97, Issue 6, 2003, Pages 599-605

  Saas Torres, J ^a   Domingo, C ^a   Moron A ^a   Rue M ^a   Marin A ^a  

^a Hospital Universitari Parc Taulí   (Spain)

Author keywords

Almitrine bismesylate; Chronic hypoxaemia; COPD

Indexed keywords

ALMITRINE DIMESILATE; PLACEBO; PSYCHOTROPIC AGENT; RESPIRATORY STIMULANT AGENT;

AGED; ANALYSIS OF VARIANCE; ARTERIAL GAS; ARTERIAL OXYGEN TENSION; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EXERCISE TEST; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HYPOXEMIA; KIDNEY DISEASE; LIVER DISEASE; LONG TERM CARE; LOW DRUG DOSE; LUNG VENTILATION PERFUSION RATIO; MAJOR CLINICAL STUDY; MALE; MUSCLE WEAKNESS; PARESTHESIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULSE OXIMETRY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SLEEP APNEA SYNDROME; SPIROMETRY;

EID: 0037975561     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1053/rmed.2003.1486     Document Type: Article

References (30)

1. Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1981; 1: 681-686.
2. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med 1980; 93: 391-398.
3. Chailleux E, Fauroux B, Binet F, et al. Predictors of survival in patients receiving domiciliary oxygen therapy or mechanical ventilation. A 10 year analysis of ANTADIR observatory. Chest 1996; 109: 741-749.
4. Connors Jr, AF, Dawson NV, Thomas Ch, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. Am J Respir Crit Care Med 1996; 154: 959-967.
5. Guyatt GH, Towsend M, Berman LB, Pugsley SO. Quality of life in patients with Chronic airflow limitation. Br J Dis Chest 1987; 81: 45-54.
6. Jones PW, Quirck FH, Baveystock CM. The St George's Respiratory Questionnaire. Respir Med 1991; 85 (Suppl B): 25-31.
7. Gherardi R, Louarn F, Benvenuti C, et al. Peripheral neuropathy in patients treated with almitrine dimesylate. Lancet 1985; 1 (8440): 1247-1250.
8. Blondel M, Arnott G, Defoort S, et al. Onze cas de neuropathies à l'Almitrine dont un avec neuropathie optique. Rev Neurol Paris. 1986; 142: 683-688.
9. Petit H, Leys D, Hurtevent JF, et al. Neuropathies et almitrine. Quatorze cas. Rev Neurol Paris. 1987; 143: 510-519.
10. Powles AC, Tuxen DV, Mahood CB, Pugsley SO, Campbell EJ. The effect of intravenously administered almitrine, a peripheral chemoreceptor agonist on patients with chronic air flow obstruction. Am Rev Respir Dis 1983; 127: 284-289.
11. Macleod CN, Thomas RW, Bartley EA, Parkhurst GW, Bachand RT. Effects and handling of almitrine bismesylate in healthy subjects. Eur J Respir Dis 1983; 126 (64): 275s-89s.
12. Voisin C, Howard P, Ansquer JC. Almitrine bismesylate: a long term placebo-controlled double blind study in COAD. Vectarion International Multicentre Study Group. Bull Eur Physiopathol Respir 1987; 23 (suppl 11): 169s-82s.
13. Weitzenblum E, Schrinjen F, Apprill M, Préfaut C, Yernault JC. One year treatment with almitrine improves hypoxaemia but does not increase pulmonary artery pressure in COPD patients. Eur Respir J 1991; 4: 1215-1222.
14. Weitzenblum E, Arnaud F, Bignon J, et al. Administration séquentielle d'une posologie réduite d'almitrine à des malades BPCO. Rev Mal Resp 1992; 9: 455-463.
15. Bardsley PA, Howard P, Tang O, et al. Sequential treatment with low dose almitrine bismesylate in hypoxaemic chronic obstructive airways disease. Eur Respir J 1992; 5: 1054-1061.
16. Papazian L, Bregeon F, Gaillat F, et al. Inhaled NO and almitrine bismesylate in patients with acute respiratory distress syndrome: effect of noradrenalin. Eur respir J 1999; 14: 1283-1289.
17. Roca J, Sanchís J, Agusti-Vidal A, et al. Spirometric reference values for a mediterrarean population. Bull Eur Physiopathol Respir 1982, 18: 101-102.
18. Guyatt GH, Towsend M, Berman LB, Pugsley SO. Quality of life in patients with Chronic airflow limitation. Br J Dis Chest 1987; 81: 45-54.
19. Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW. A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987; 42: 772-778.
20. Güell R, Casan P, Sargenís M, et al. Traducción española y validación de un cuestionario de calidad de vida en pacientes con enfermedad pulmonar obstructiva crónica. Arch Bronconeumol 1995; 31: 202-210.
21. Préfaut Ch, Bourgouin-Karaouni D, Ramonatxo M, Michel FB, Macabies J. A one year double blind follow up of blood gas tensions and haemodynamics in almitrine bismesylate therapy. Eur Respir J 1988; 1: 41-50.
22. Böhning W, Winkelmann B, Worth H et al. Long term therapy with almitrine dimesilate has no effect on pulmonary hemodynamics at rest and during stress. Pneumologie 1990; 44 (suppl 1): 444-445.
23. Winkelmann BR, Kullner Th H, Kneissl DG, Dietmar Trenk and Hartmut Kronenberger. Low dose almitrine bismesylate in the treatment of hypoxemia due to chronic obstructive pulmonary disease. Chest 1994; 105: 1383-1391.
24. Bakran I, Vrhovac B, Stangl B et al. Double blind placebo controlled clinical trial of almitrine bismesylate in patients with chronic respiratory insufficiency. Eur J Clin Pharmacol 1990; 38: 249-53.
25. González Ruiz JM, Villamor J, Pino JM, Muñoz J, Lobato SD, Prados C. Parámetros predictivos en la respuesta al tratamiento con almitrina. Arch Bronconeumol 1994; 30: 141-4.
26. Nowak D, Wywiol A, Magnussen H. Almitrine in therapy of chronic obstructive respiratory tract diseases with hypoxemia: a clinical multicenter study comparing 2 dosages. Pneumologie 1998; 52: 121-7.
27. Marrone O, Milone F, Coppola P et al. Effects of almitrine bismesylate on nocturnal hypoxemia in patients with chronic bronchitis and obesity. Eur J Respir Dis 1986; 146: 641s-8s.
28. Gothe B, Cherniak NS, Bachand Jr, RT, Szlkowski MB, Bianco KA. Long term effects of almitrine bismesylate on oxygenation during wakefulness and sleep in chronic obstructive pulmonary disease. Am J Med 1988; 84: 436-4.
29. Escourrou P, Simonneau G, Ansquer JC, Duroux P, Lockart A. A single orally administered dose of almitrine improves pulmonary gas exchange during exercise in patients with chronic air-flow obstruction. Am Rev Respir Dis 1986; 133: 562-567.
30. McNee W, Connaughton JJ, Rhind GB, et al. A comparison of the effects of almitrine or oxygen breathing on pulmonary arterial pressure and right ventricular ejection fraction in hypoxic chronic bronchitis and emphysema. Am Rev Respir Dis 1986; 134: 559-565.